New data on long-term, real-world treatment with lecanemab presented at the 2026 AD/PD™ congress

Eisai presented new real-world data on long-term treatment persistence with IV lecanemab in US early Alzheimer’s patients at the AD/PD conference (Mar 17-21, 2026). BioArctic also delivered an oral presentation on lecanemab and a poster on exidavnemab. The persistence findings could influence adoption and reimbursement expectations for lecanemab, but no efficacy, safety or commercial figures were reported, so expect limited near-term market impact absent further data or regulatory/commercial developments.

Analysis

Real‑world persistence data for IV lecanemab materially shifts the adoption story from “efficacy proof” to “operational scaling.” If persistence at 6–12 months holds above ~70%, payors and hospitals will have clearer visibility on utilization curves and total cost of care, accelerating negotiated coverage decisions within 6–18 months. Conversely, persistence dropping below ~50% would immediately compress revenue math and create downward pricing pressure from Medicare Advantage and PBMs.

Second‑order winners are service providers that sit between drug and patient: infusion centers, MRI vendors, and specialty pharmacies — these capture recurring revenue per patient (infusion + serial MRIs) and face a near‑term capacity squeeze. That creates a tangible capex cycle for imaging manufacturers (incremental MRI purchases/maintenance) and a hiring/contracting spike for outpatient infusion networks over the next 12–24 months. Downstream losers include one‑trick small biotech names whose valuations hinge on a single amyloid program and hospital systems unable to scale outpatient infusion, which will see margin compression and patient leakage.

Key tail risks are payer pushback, faster emergence of SC formulations or home‑infusion that undercut hospital margins, and ARIA‑driven label narrowing after broader use; any of these can flip the revenue curve within a 3–12 month window. Near‑term catalysts to watch: national Medicare coverage policy updates, major MA plan formulary decisions, and filings from competitors on SC formulations or head‑to‑head persistence data — any surprise here can move equity spreads by 20–40% in a quarter. Operational milestones (infusion center buildouts, MRI utilization rates) will be as predictive of revenue as clinical endpoints over the next 12–18 months.

Key Decisions for Investors

• Overweight Biogen (BIIB) — tactical 9–12 month exposure via call options or a modest equity add: thesis is continued real‑world persistence drives revenue share upside and lowers payor friction. Risk: reimbursement reversal or ARIA-driven label limits; position size 2–4% notional, target 30–50% upside, stop if negative Medicare guidance within 3 months.
• Long medical‑device / imaging exposure (GE, ticker GE) — buy-and-hold 12–24 months to capture incremental MRI demand and service contracts from amyloid therapy rollout. Size 1–2% position, target 20–30% upside as MRI utilization improves; downside risk is delayed hospital capex if payors cap utilization.
• Pair trade: long BIIB / short a small single‑program Alzheimer biotech (example short candidate: SAVA) — rationale is dispersion between diversified commercial upside versus binary trial/coverage risk. Keep pair dollar‑neutral, small size (1% each), aim for asymmetric payoff if payors consolidate on proven players; tighten losses if macro liquidity dries up.
• Hedge: buy 6–9 month BIIB put spreads to protect core exposure ahead of major payer announcements (Medicare/MA formulary). Costly outright hedges can be financed by selling short‑dated calls; target hedge to cap downside at ~25–30% for the event window.